Exploratory Evaluation of Neopterin and Chitotriosidase as Potential Circulating Biomarkers for Colorectal Cancer.
biomarkers
chitotriosidase
colorectal cancer
neopterin
systemic inflammation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
20
02
2023
revised:
07
03
2023
accepted:
08
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Chronic inflammation is demonstrated to play a direct role in carcinogenesis. Our exploratory study aimed to assess the potential added value of two inflammation biomarkers, chitotriosidase and neopterin, in follow-up evaluation of patients with colorectal cancer (CRC). An observational exploratory study was conducted. Patients with CRC and matched controls (1:1, age, sex, and living environment) were evaluated. The patients with CRC (CRC group) and controls were assessed at baseline (before surgical intervention for patients with CRC). Patients with CRC were also evaluated at 1-year follow-up. Significantly more patients with blood group A (54.5% vs. 25.0%) and smokers (50.0% vs. 22.7%) were in the CRC group. The serum values of chitotriosidase and neopterin were higher in CRC patients than in controls, but only neopterin reached the conventional level of statistical significance (
Identifiants
pubmed: 36979873
pii: biomedicines11030894
doi: 10.3390/biomedicines11030894
pmc: PMC10046191
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Iuliu Hațieganu" University of Medicine and Pharmacy of Cluj-Napoca
ID : 2461/8/22/17.01.2020
Références
Diagnostics (Basel). 2021 Feb 08;11(2):
pubmed: 33567717
J Inherit Metab Dis. 1995;18(6):717-22
pubmed: 8750610
Nature. 2004 Sep 23;431(7007):405-6
pubmed: 15385993
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1017-20
pubmed: 21415359
Ann Oncol. 2018 Feb 1;29(2):472-483
pubmed: 29244072
Int Immunol. 2005 Nov;17(11):1505-12
pubmed: 16214810
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Oncotarget. 2016 Jun 28;7(26):39572-39581
pubmed: 27153562
J Biol Chem. 1995 Feb 3;270(5):2198-202
pubmed: 7836450
Int J Mol Sci. 2019 Oct 24;20(21):
pubmed: 31653078
Respiration. 2007;74(5):548-52
pubmed: 17347558
Ann Gastroenterol Surg. 2021 Nov 10;6(2):204-211
pubmed: 35261946
J Clin Med. 2022 Jun 23;11(13):
pubmed: 35806923
Int J Cancer. 2008 Sep 1;123(5):1160-5
pubmed: 18546286
Oncogene. 2012 Jun 28;31(26):3111-23
pubmed: 22056877
Immunol Lett. 2009 Apr 27;123(2):97-102
pubmed: 19428556
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
J Natl Cancer Inst. 2015 Feb 23;107(4):
pubmed: 25713165
Immun Ageing. 2016 Feb 25;13:5
pubmed: 26918023
Cancer. 2014 Nov 1;120(21):3370-7
pubmed: 24948355
Int J Mol Sci. 2020 Jul 27;21(15):
pubmed: 32726923
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404
pubmed: 31496619
Diseases. 2018 Dec 11;6(4):
pubmed: 30544946
Oncotarget. 2017 Apr 25;8(17):29519-29534
pubmed: 28392501
PLoS One. 2018 Apr 9;13(4):e0195354
pubmed: 29630649
BMC Cancer. 2019 Jun 25;19(1):629
pubmed: 31238895
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Ann Lab Med. 2019 May;39(3):284-290
pubmed: 30623620
Antioxidants (Basel). 2018 Jun 26;7(7):
pubmed: 29949851
Dis Colon Rectum. 1987 Nov;30(11):879-83
pubmed: 3479311
Respir Res. 2020 Jan 6;21(1):6
pubmed: 31906975
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):596-602
pubmed: 30641772
Cancer Control. 2022 Jan-Dec;29:10732748211056692
pubmed: 35000418
PLoS One. 2017 Sep 7;12(9):e0184295
pubmed: 28880901
J Am Coll Surg. 2013 Aug;217(2):181-90
pubmed: 23768788
Clin Chem. 2001 Apr;47(4):624-30
pubmed: 11274010
Cancer Biomark. 2017 Jul 4;19(4):383-391
pubmed: 28582842
Ann Clin Lab Sci. 2017 Nov;47(6):713-719
pubmed: 29263045